The introduction of the use of the prostate-specific antigen (PSA) test in 1987 as a screening tumour marker increased the incidence of PCa [4] but also initiated three decades of debate about the specificity of the PSA test and associated overdiagnosis and overtreatment [5,6,7,8]. The gene discussed is KLK3; the disease is posterior cortical atrophy.